Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
2028. márc. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Multi-CAR-T Cells Targeting B Cell Lymphomas
2027. jún. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer
2027. febr. 26.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
2027. febr. 1.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
New diagnostic pathway in primary diagnosis of clinically significant prostate cancer adding PSMA-PET to mpMRI
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTIS
Vizsgálat
PSMA-specific CAR-T Cell Therapy
2026. dec. 31.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
2026. dec. 31.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
GD2/PSMA Bi-specific CAR-T Cell Therapy
2026. dec. 31.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer
2026. dec. 30.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Safety and Efficacy of OTL78
2026. dec. 1.· PHASE2_PHASE3 · RECRUITING· CTGOV
Vizsgálat
POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions
2026. dec. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
2026. dec. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
2026. nov. 15.· PHASE2 · RECRUITING· CTGOV
Publikáció
Patient Communication and Radiation Safety in [177Lu]Lu-PSMA Radiopharmaceutical Therapy: International Survey of 102 Theranostic Centers.
2026. nov. 5.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
Preclinical Physiologically Based Pharmacokinetic Modeling of PSMA Radioligands: Demonstrating Nonspecific Retention and Reversible Albumin-Binding Effects.
2026. nov. 5.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
PSMA PET Before Prostate Biopsy: From Lesion Detection to Biopsy Avoidance.
2026. nov. 4.· The French journal of urology· PUBMED
Publikáció
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer.
2026. nov. 3.· Molecular cancer therapeutics· PUBMED
Publikáció
Dural Metastases from Prostate Cancer Mimicking Meningioma on PSMA PET/CT.
2026. nov. 3.· Revista espanola de medicina nuclear e imagen molecular· PUBMED
Vizsgálat
Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
2026. nov. 2.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Fully Automated Segmentation of [18F]FDG and [68Ga]/[18F]PSMA PET/CT Images via Data-Centric Deep Learning.
2026. nov. 2.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
2026. nov. 2.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177Lu-PSMA Therapy Between Centers in Brazil and Europe.
2026. nov. 2.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
The PRIMARY Scoring System on PSMA PET for Clinically Significant Prostate Cancer Detection: A Systematic Review and Meta-Analysis: Erratum.
2026. nov. 2.· Clinical nuclear medicine· PUBMED
Publikáció
Prognostic Value of [18F]FDG PET Combined with [68Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617.
2026. nov. 2.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.
2026. nov. 2.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Vizsgálat
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
2026. nov. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTIS
Vizsgálat
Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma
2026. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV